香港2026年8月6日 /美通社/ -- 近日，英國知名金融行業雜誌《全球銀行與金融評論》（Global Banking and Finance Review）公佈2026年度獲獎名單，復星國際有限公司（香港聯交所股份代號：00656）憑借在可持續發展與企業社會責任領域的卓越貢獻，以及日益提升的全球品牌影響力，一舉斬獲三項大獎。

復星國際此次榮獲：「ESG及可持續發展獎－2026年亞洲最佳可持續發展企業獎」、「企業社會責任獎－2026年亞洲最佳企業社會責任公司獎」及「品牌獎－2026年亞洲最佳控股集團品牌獎」，充分印證了復星在可持續發展戰略執行、公司治理體系完善、社會責任履行及環境保護等維度所取得的進展，亦是對其長期以來堅持透明化運營、積極構建利益相關方溝通機制的整體肯定。

《全球銀行與金融評論》指出，復星國際此次獲獎，源於其在多個維度的均衡發展與突出表現：在業務層面，復星通過持續優化全球產業生態佈局，實現了核心業務的穩健增長與抗週期韌性；在可持續發展層面，公司將ESG理念深度融入戰略決策與日常運營，展現出清晰的路徑規劃與堅定的執行決心。評委會特別強調，復星在推動商業價值與社會價值協同發展方面的實踐，為亞洲乃至全球的企業提供了有益參照。

ESG評級屢獲佳績，可持續發展戰略深入推進

復星已將可持續發展提升至企業戰略核心，並提出了「創造影響力」（Create IMPACT）的可持續發展戰略，明確了創新驅動、責任運營、以人為本、精益治理、綠色發展和透明真實六大長期方向。2026年度，復星在ESG領域迎來全面突破：其MSCI ESG評級躍升至最高的AAA級，這是自2021年獲評AA以來歷經五年深耕實現的重大跨越，標誌着綜合管理水平達到全球同業領先水平。與此同時，復星在富時羅素ESG評分中升至4.2分（滿分5分），並連續第五次入選「富時羅素社會責任指數」成份股，在國際權威指數機構的評級體系中持續保持領先身位。

國際主流可持續發展評估持續提升，復星成功入選標普全球《可持續發展年鑑2026》，並在《可持續發展年鑑（中國版）2026》中連續第三年名列中國最佳1%。此外，復星還斬獲了香港管理專業協會「卓越環境、社會及管治報告嘉許獎」、《金融衍生工具》雜誌「香港最佳ESG公司」獎、《財富》「最受贊賞中國公司榜單『行業明星榜，以及亞洲企業管治』亞太區可持續發展大獎」和「最佳環境責任獎」等一系列獎項，充分展現了業界對復星全方位ESG工作的高度認可。

立業為善，積極回饋社會

作為負責任的企業公民，復星於2012年成立復星基金會，在全球應急馳援、鄉村振興、健康醫療、教育文化等領域持續創造社會價值。

復星不斷深耕鄉村振興與基層健康領域，「鄉村醫生計劃」自2017年啓動以來，已累計守護2.5萬名鄉村醫生，惠及300萬戶農村家庭，該項目更入選了聯合國全球契約組織「二十年二十佳」企業可持續發展案例。復星國際董事長郭廣昌不久前專程前往江西廣昌縣，回訪了復星鄉村醫生項目已守護九年的村醫老友，他感慨道：「每次跟這些鄉村醫生聊完，都覺得這件事做對了，這是復星做公益的初心。」管理層身體力行的長期關注，正不斷為項目注入持續前行的動力。2026年第二季度，「AI村醫助手2.0」正式發佈，新增化驗單與體檢報告智能解讀功能，並以更貼合村醫實際工作場景的交互體驗，切實提升基層診療效率。

面對突發災情，復星基金會展現出高效的響應能力。2026年7月，廣西遭遇罕見洪澇災害，基金會第一時間啓動馳援機制，近60萬件救援物資迅速送抵一線，以「快0.01秒」的專業行動為受災群眾和救援隊伍提供發電機、自熱飯等急需保障，生動詮釋了其始終如一的公益初心與執行力。

復星持續助力青年創業及全球創新，復星基金會聯合復星葡萄牙保險Fidelidade、葡萄牙醫療集團Luz Saúde等機構共同發起的第八屆「Protechting全球青年創新創業大賽」再創佳績。賽事聚焦保險科技、醫療科技、人工智能及ESG可持續發展等前沿領域，共吸引來自50餘個國家和地區的637個項目申請，數量創歷史新高；賽事不僅為入圍團隊提供80餘場導師面對面及企業深潛日等深度孵化支持，還積極搭建中歐創新橋樑——13支國際科創團隊將受邀參加2026年金秋中國路演，前往香港、佛山、澳門、珠海、上海等地對接產業資源與投資機構。從葡萄牙到中國，Protechting持續構建跨越洲際的科創交流平台，讓全球青年創新力量在中國及國際市場生根發芽，踐行「科創+公益」模式的長期承諾。

創新驅動發展，AI與健康領域惠及民生

復星始終堅持「以解決實際問題為出發點」，將人工智能深度融入醫藥健康與智慧服務等核心產業。在研發端，復宏漢霖AI蛋白藥物智能設計平台僅用3個月便將核心項目藥物分子親和力提升20倍以上，大幅加速新藥問世；在服務端，復星旅文推出「AI G.O」智能管家，將傳承數十年的非標服務經驗轉化為7X24小時在線的數字資產，為遊客提供有溫度的個性化體驗。同時，復星還積極推動技術向善，其「AI村醫助手」已面向2.5萬名鄉村醫生推廣應用，以92%的用戶滿意度切實賦能基層醫療末梢，讓科技創新成果惠及最需要的人群。

復星旗下健康產業始終秉承為更多患者帶來治癒希望的初心，深度佈局腫瘤、免疫炎症、神經退行性疾病等核心治療領域，並積極拓展慢病及罕見病，打造具有長期競爭力的產品管線。持續夯實抗體、ADC、小分子、細胞治療等核心技術平台，並拓展核藥、小核酸等前沿技術，取得了一系列惠及全球患者的突破性成果：漢斯狀®作為全球首個一線治療廣泛期小細胞肺癌的PD-1單抗，已在40餘個國家和地區上市；HLX43在非小細胞肺癌、婦科腫瘤等多個領域展現「高效、低毒」優勢；HLX22則是全球首款同時獲歐盟與美國孤兒藥資格認定的胃癌抗HER2靶向療法。

與此同時，復星醫藥致力於提升藥物可及性，為推動「無瘧疾世界」的全球願景持續貢獻中國力量，截至2025年底，其自主研發的注射用青蒿琥酯已累計救治全球超8,800萬重症瘧疾患者，累計供應超過4.4億支。

展望未來，復星國際將繼續深化「創造影響力」的可持續發展戰略，通過創新和負責任的運營，積極承擔更多社會責任，致力於創造更加負責任、包容和可持續的未來。

HONG KONG, Aug. 6, 2026 /PRNewswire/ -- Recently, Global Banking and Finance Review, a leading British financial magazine, announced its 2026 award winners. Fosun International Limited (HKEX stock code: 00656) received three awards in recognition of its outstanding contributions to sustainable development and corporate social responsibility (CSR), as well as its growing global brand influence.

Fosun International received the "ESG & Sustainability Awards – Best Sustainable Development Company Asia 2026", "CSR Awards – Best CSR Company Asia 2026", and "Brand of the Year Awards – Holding Group Brand of the Year Asia 2026". These accolades underscore the progress it has made in executing its sustainable development strategy, strengthening corporate governance, fulfilling its social responsibility and advancing environmental protection, while also affirming its long‑standing commitment to transparent operations and proactive stakeholder communication.

Global Banking and Finance Review highlighted that Fosun's recognition in these awards reflects its balanced development and outstanding performance across multiple areas. On the business front, Fosun has continued to optimize its global industrial ecosystem, delivering resilient growth in its core businesses and strengthening its ability to navigate economic cycles. On the sustainability front, the company has integrated ESG principles into both strategic decision-making and day-to-day operations, underpinned by a clear roadmap and strong execution. The judging panel particularly emphasized that Fosun's efforts to align commercial value with social value offer a valuable reference for companies in Asia and globally.

Outstanding ESG Performance and Continued Advancement of Sustainable Development Strategy

Fosun has embedded sustainable development at the heart of its corporate strategy and introduced the "Create IMPACT" sustainable development strategy, which sets out six long-term directions: Innovation-Driven, Mindful Operation, People and Partner Oriented, Advanced Governance, Climate and Planet Positive, and Transparency. In 2026, Fosun achieved a comprehensive breakthrough in Environmental, Social, and Governance (ESG) performance. Its MSCI ESG rating has been upgraded to the highest rating AAA, marking a significant milestone after five years of sustained effort since first receiving an AA rating in 2021 and indicating that its overall management standards have reached a leading position among global peers. Meanwhile, Fosun's FTSE Russell ESG score rose to 4.2 (maximum score: 5) and has been included in the FTSE4Good Index Series for the fifth consecutive time, maintaining a leading position in the rating systems of internationally recognized index providers.

Fosun has also achieved steady improvement in mainstream international sustainability assessments. It has been included in S&P Global's Sustainability Yearbook 2026 and, for the third consecutive year, ranked among the top 1% in the Sustainability Yearbook (China Edition) 2026. Furthermore, Fosun garnered a number of awards, including the "Certificate of Excellence in Environmental, Social and Governance Reporting" from Hong Kong Management Association, "Best ESG Company Hong Kong" from the magazine Financial Derivative, recognition in Fortune's "Most Admired Chinese Companies" list, and "Sustainable Asia Award" and "Best Environmental Responsibility Award" from Corporate Governance Asia, all of which underscore the industry's strong recognition of Fosun's comprehensive ESG efforts.

Fosun for Good, Actively Giving Back to Society

As a responsible corporate citizen, Fosun established Fosun Foundation in 2012, continuously creating social value in areas such as global emergency relief, rural revitalization, healthcare, and education and culture.

Fosun has continued to deepen its commitment to rural revitalization and primary healthcare. Since its launch in 2017, the Rural Doctors Program has supported 25,000 rural doctors and benefited 3 million rural families. The program was also selected as one of the UN Global Compact's "20 Cases of Private Sector's Sustainable Development in China for 20 Years". Recently, Guo Guangchang, Chairman of Fosun International, made a trip to Guangchang County, Jiangxi Province, to visit rural doctors who have been supported by Fosun's Rural Doctors Program for nine years. He said, "Every time I speak with rural doctors, I feel even more strongly that we are doing the right thing. This reflects Fosun's original aspiration in supporting philanthropy." The management's long-term commitment and hands-on approach have continued to drive the program forward. In the second quarter of 2026, Fosun launched "AI Rural Doctor Assistant 2.0", adding intelligent interpretation of lab reports and physical examination reports, alongside an interactive experience tailored to the actual workflows of rural doctors, thereby effectively enhancing primary healthcare efficiency.

In the face of sudden disaster, Fosun Foundation has demonstrated its efficient response capability. In July 2026, Guangxi was struck by a severe, devastating flood. Fosun Foundation immediately activated its emergency relief mechanism and rapidly delivered nearly 600,000 relief items to the front lines. Driven by a "0.01 second faster" mindset, it provided urgently needed supplies such as generators and self-heating meals to the affected people and rescue teams, demonstrating its enduring commitment to philanthropy and strong execution.

Fosun has also continued to support youth entrepreneurship and global innovation. The 8th edition of the "Protechting Open Innovation Program" jointly launched by Fosun Foundation, Fidelidade, and Luz Saúde, reached new heights this year. Focused on cutting-edge areas such as insurtech, medtech, artificial intelligence (AI), and ESG, the program received 637 applications from more than 50 countries and regions, setting a new record. In addition, the program provided deep incubation support, including over 80 mentor sessions and corporate immersion days for shortlisted teams. It also served as a bridge connecting Europe and China. Thirteen international technology innovation teams have been invited to participate in roadshows across Hong Kong, Foshan, Macau, Zhuhai, and Shanghai this autumn, where they will connect with industry resources and investment institutions. From Portugal to China, Protechting is steadily building an intercontinental platform for innovation exchange, helping young innovators from around the world to take root in China and beyond, and reflecting its long-term commitment to the "technology innovation + philanthropy" model.

Innovation-Driven Growth, Bringing AI and Healthcare Benefits to the Public

Fosun has consistently prioritized solving real-world problems and has deeply integrated AI into its core businesses, including pharmaceuticals, healthcare and intelligent services. On the research and development (R&D) front, Henlius' AI-powered protein drug design platform has increased the binding affinity of a core project molecule by more than 20 times in just three months, significantly accelerating the development of new drugs. On the service front, Fosun Tourism Group has launched the AI G.O intelligent system, transforming decades of non-standard service experience into a 24/7 digital asset to deliver more personalized and thoughtful experiences for guests. Fosun has also been actively advancing technology for social good. Its "AI Rural Doctor Assistant" has been rolled out to 25,000 rural doctors, with a user satisfaction rate of 92%, effectively empowering grassroots primary healthcare and bringing the benefits of technology innovation to those who need them most.

Fosun's Health business remains committed to bringing new hope of cure to more patients. It has established a deep presence in core therapeutic areas such as oncology, immunology and inflammation, and neurodegenerative diseases, while actively expanding into cardiometabolic diseases and rare diseases. This approach enables the development of high valued competitive pipelines and comprehensive healthcare solutions. Meanwhile, it continues to consolidate its core technical platforms including antibodies, antibody-drug conjugates (ADCs), small molecules and cell therapies, while expanding into cutting-edge therapeutic modalities such as radiopharmaceuticals and small nucleic acids. It has achieved a series of breakthroughs that are benefiting patients worldwide. As the world's first monoclonal antibody targeting PD-1 approved for first-line treatment of extensive-stage small cell lung cancer (ES-SCLC), HANSIZHUANG has been approved for marketing in over 40 countries and regions. HLX43 has shown significant advantages, with a favorable efficacy and safety profile in non-small cell lung cancer (NSCLC), gynecological tumors, and other indications. HLX22 is the world's first anti-HER2-targeted therapy to receive Orphan Drug Designation (ODD) approvals from both the US Food and Drug Administration (FDA) and the European Commission (EC) for gastric cancer.

At the same time, Fosun Pharma is committed to enhancing medication accessibility and contributing to the global vision of a "malaria-free world". As of the end of 2025, Fosun Pharma's independently developed artesunate for injection had saved more than 88 million patients with severe malaria worldwide, with more than 440 million vials supplied globally.

Looking ahead, Fosun will continue to deepen its "Create IMPACT" sustainable development strategy, actively taking on greater social responsibility through innovation and responsible operations, and endeavoring to build a more responsible, inclusive, and sustainable future.

NVIDIA Corporation (NVDA.US) is accelerating its foray into the telecom operator market and is seeking base station manufacturing partners in China to develop 6G base stations that meet overseas market requirements, with the aim of entering trial networks in 2027 or 2028, Jiemian News reported, citing sources.

NVIDIA purportedly believes computing power ultimately needs to rely on wireless transmission via base stations in order to transfer from data centers to massive numbers of AI terminals and users. The company is therefore searching for the “next ZJ INNOLIGHT (03308.HK)” in edge computing power.

Shenzhen Signalwing Technology is one of NVIDIA's developing base station partners, sources said. The two parties began contacts in 2025 and are jointly developing 6G AI-RAN base stations based on the NVIDIA CUDA ecosystem. Their cooperation has continued for more than six months, and a dedicated working group has already been formed, involving more than 10 NVIDIA personnel based in Singapore, Hong Kong and Mainland China.

TONGYU COMM (002792.SZ) acquired an approximately 25% stake in Shenzhen Signalwing Technology for RMB300 million on August 4.

Besides, the cooperation between Shenzhen Signalwing Technology and NVIDIA has reportedly entered the technology R&D stage. The duo may also establish a commercial entity jointly for overseas expansion.
~

AASTOCKS Financial News
Website: www.aastocks.com

Meta Platforms, Inc. (META.US) launched its first coding agent, named Muse Code, to challenge leading AI labs Anthropic and OpenAI.

Muse Code marks the latest major product launch by AI chief Alexandr Wang, who leads Meta Superintelligence Labs and oversees foundation model development. He joined Meta in June 2025 and became a key member in CEO Mark Zuckerberg's overhaul of the company's AI strategy.

The tool is similar to Anthropic's Claude and OpenAI's Codex assistant, allowing users to build applications within a single interface while managing AI-powered digital agents to support software development workflows.
~

AASTOCKS Financial News
Website: www.aastocks.com

Alphabet Inc. (GOOGL.US) announced that its AI division is undergoing restructuring. Chief Scientist Jeff Dean, who has served the company for 27 years, will leave the company, while Google DeepMind CEO Demis Hassabis will become Chairman of Google DeepMind and concurrently serve as Chief Scientist of Alphabet.

Following the announcement, Alphabet shares slumped 4.05% on Wednesday (5th) to USD360.13.

Dean, a pioneer in the AI field who helped drive multiple key technological breakthroughs at Google, will co-found a new company with Alphabet Senior Fellow Sanjay Ghemawat. Alphabet will also invest in the startup.
~

AASTOCKS Financial News
Website: www.aastocks.com

SAN FRANCISCO and SUZHOU, China, Aug. 6, 2026 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures, and commercializes high-quality medicines for the treatment of oncology, autoimmune, cardiovascular and metabolic, ophthalmology, and other major diseases, announced that the first patient has been dosed in a pivotal study evaluating IBI363 (Takeda R&D code: TAK-928), a potential first-in-class PD-1/IL-2^α-biased bispecific fusion protein, in combination with bevacizumab versus investigator's choice of therapy, in patients with advanced colorectal cancer (CRC) that is refractory or intolerant to standard treatment.

This is the third pivotal registrational clinical study initiated for IBI363 and marks a critical step forward for investigational next-generation immuno-oncology (IO) therapies in overcoming colorectal cancer—a classic 'immune-cold' tumor. Previously initiated studies of IBI363 include a pivotal Phase 2 clinical study (NCT07217301) in China for IO-naïve melanoma (acral and mucosal subtypes). A global, multi-center, Phase 3 clinical study (NCT06797297) in IO-resistant squamous non-small cell lung cancer (NSCLC) has also been initiated. As part of a license and collaboration agreement, Innovent and Takeda are co-developing IBI363/TAK-928 globally and will co-commercialize IBI363/TAK-928 in the U.S. Takeda will exclusively commercialize IBI363/TAK-928 worldwide outside of the U.S. and greater China.

This trial (NCT07722494) is a multicenter, randomized, open-label, Phase 3 clinical study designed to evaluate the efficacy and safety of IBI363 in combination with bevacizumab compared with investigator's choice of therapy in patients with advanced colorectal cancer who have failed or are intolerant to standard therapies. A total of 550 patients are planned to be enrolled. The primary endpoint of this study is overall survival (OS). This study is being conducted in China where Innovent holds development and commercialization rights for IBI363/TAK-928.

At the 2025 ASCO Annual Meeting, data from a Phase 1 clinical study of IBI363 for the treatment of advanced colorectal cancer was presented as an oral presentation. IBI363 in combination with bevacizumab demonstrated encouraging efficacy signals and a manageable safety profile. [link]

• Among patients treated with IBI363 in combination with bevacizumab (n=73), the overall confirmed objective response rate (cORR) was 15.1%, and the disease control rate (DCR) was 61.6%. With a median follow-up of 9.9 months, the progression-free survival (PFS) reached 4.7 months. With a median follow-up of 9.4 months, overall survival (OS) data remained immature, with only 13 events (17.8%) observed.
• The overall safety profile was clinically manageable, and no new safety signals were observed. The incidence of Grade 3 or higher treatment-related adverse events (TRAEs) in the combination therapy group was 35.6%. The most common TRAEs were arthralgia, anemia, rash, and hypothyroidism.

Based on updated long-term follow-up data from the above study, IBI363 in combination with bevacizumab was granted Breakthrough Therapy Designation (BTD) by the Center for Drug Evaluation (CDE) of China's National Medical Products Administration (NMPA) in May 2026. The proposed indication is for patients with advanced microsatellite stable (MSS) or mismatch repair-proficient (pMMR) colorectal cancer (CRC) who have progressed on ≥ 2 lines of prior standard therapy. The updated study results are planned for presentation at a future international academic conference or publication in an international academic journal.

Professor Kefeng Ding from the Second Affiliated Hospital of Zhejiang University School of Medicine, the principal investigator of this study, stated: "Colorectal cancer is a common gastrointestinal malignancy that poses a severe threat to human health. Worldwide, it ranks third in incidence and second in mortality among all malignant tumors^[1]. Approximately 86% of colorectal cancers are in an immune-desert or immune-suppressed state, rendering them unresponsive to traditional immune checkpoint inhibitors (ICIs)^[2]. For patients with colorectal cancer who have failed standard therapy, treatment options are limited, survival is short, and there remains a huge unmet clinical need^[3-5]. As a PD-1/IL-2α-biased bispecific molecule, IBI363's dual antitumor mechanism—blocking PD-1 while stimulating tumor-specific CD8⁺ T cells (TST cells)—holds the promise of turning 'cold' tumors 'hot'. Early data for IBI363 in combination with bevacizumab in late-line treatment have demonstrated encouraging, breakthrough efficacy along with tolerable safety, showing potential to become a novel immunotherapy for colorectal cancer. I will work closely with other investigators to advance and complete this pivotal clinical study, steadily generating high-quality clinical data to provide colorectal cancer patients with a more effective treatment option."

Professor Tao Zhang from Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, the principal investigator of this study, stated: "For patients with advanced colorectal cancer (CRC), treatment options become extremely limited after the failure of second-line or later therapies. In particular, patients with MSS CRC—who represent the vast majority of colorectal cancer cases—are largely insensitive to current immune checkpoint inhibitors. Chemotherapy or anti-angiogenic agents offer limited efficacy and fail to deliver durable disease control, leaving patients in urgent need of effective late-line treatment options. IBI363, featuring a unique PD-1/IL-2^α-biased dual immuno-activation mechanism, holds the potential to overcome the immunosuppressive state of 'cold tumors.' The early clinical data for IBI363 in combination with bevacizumab are highly encouraging. As a clinician, I look forward to the initiation and progress of the Phase 3 clinical study, hoping it will soon bring meaningful treatment choices and renewed hope of survival to patients with late-line colorectal cancer."

Dr. Hui Zhou, Chief R&D Officer (Oncology) of Innovent, stated: "IBI363 represents the evolutionary direction of next-generation immunotherapy—not only potentially improving on the survival benefits of existing IO therapies, but also striving to overcome 'cold' tumors that traditional IO treatments cannot effectively address. Early clinical data demonstrate that IBI363 in combination with bevacizumab achieves significant responses and long-term survival benefits in non-MSI-H/pMMR advanced colorectal cancer, validating its unique mechanism and broad-spectrum potential. Currently, the first batch of core indications for IBI363 has smoothly entered pivotal registration clinical trials. We look forward to offering a new choice for colorectal cancer patients and bringing hope to broader unaddressed areas in immunotherapy."

About MSS/pMMR Colorectal Cancer

Colorectal cancer (CRC) is one of the most common malignancies worldwide, with MSS/pMMR being the predominant subtype, accounting for approximately 95% of advanced CRC cases. For patients with advanced MSS/pMMR CRC who have failed standard therapies, there remains a significant unmet medical need. Treatment options are limited, and prognosis remains poor (mPFS 1.9~5.6 months, mOS 6.4~10.8 months^[3-5]).

About IBI363/TAK-928 (PD-1/IL-2^α-biased bispecific fusion protein)

IBI363 is a first-in-class PD-1/IL-2α-biased bispecific antibody fusion protein being co-developed by Innovent Biologics and Takeda (Takeda R&D code: TAK-928). It functions by both blocking the PD-1/PD-L1 pathway and activating the IL-2 pathway. The IL-2 arm of IBI363 is designed to maintain its affinity for IL-2Rα while reducing binding to IL-2Rβ and IL-2Rγ, thereby minimizing toxicity. The PD-1 binding arm not only blocks PD-1 but also selectively delivers IL-2. This approach targets and activates tumor-specific T cells that express both PD-1 and IL-2α, leading to more precise and effective activation of this T cell subpopulation.

IBI363 is being evaluated in a series of clinical trials globally, including:

• A pivotal Phase 2 study in China in previously untreated acral and mucosal melanoma
• A global, multi-center Phase 3 study in immunotherapy-resistant squamous NSCLC
• A pivotal Phase 3 study in China in advanced CRC refractory or intolerant to standard treatment

In parallel, multiple Phase 1b/2 trials are evaluating IBI363 in NSCLC and CRC including the first-line and later line settings, and in additional tumor types.

IBI363 has received two Fast Track Designations (FTD) from the U.S. FDA and three Breakthrough Therapy Designations (BTD) from China NMPA so far.

In October 2025, Innovent entered into a license and collaboration agreement with Takeda, under which Innovent and Takeda will co-develop IBI363/TAK-928 globally and co-commercialize IBI363/TAK-928 in the U.S., and Takeda will exclusively commercialize IBI363/TAK-928 worldwide outside of the U.S. and greater China.

About Innovent Biologics

Innovent is a leading biopharmaceutical company founded in 2011 with the mission to empower patients worldwide with affordable, high-quality biopharmaceuticals. The company discovers, develops, manufactures and commercializes innovative medicines that target some of the most intractable diseases. Its pioneering therapies treat cancer, cardiovascular and metabolic, autoimmune and eye diseases. Innovent has launched 19 products in the market. It has 1 asset under NMPA review, 5 assets in phase 3 or pivotal clinical trials, and 14 more molecules in early clinical stage. Innovent partners with over 30 global healthcare companies, including Eli Lilly, Roche, Takeda, Pfizer, Sanofi, Incyte, LG Chem and MD Anderson Cancer Center.

Guided by the motto, "Start with Integrity, Succeed through Action," Innovent maintains the highest standard of industry practices and works collaboratively to advance the biopharmaceutical industry so that first-rate pharmaceutical drugs can become widely accessible.

For more information, visit www.innoventbio.com, or follow Innovent on Facebook and LinkedIn.

Statement: Innovent does not recommend the use of any unapproved drug (s)/indication (s).
Ramucirumab Injection (Cyramza^®), Selpercatinib Capsules (Retsevmo^®), Pirtobrutinib Tablets (Jaypirca^®) and abemaciclib (Verzenios^®) are products discovered and developed by Eli Lilly.

Forward-looking statement

This news release may contain certain forward-looking statements that are, by their nature, subject to significant risks and uncertainties. The words "anticipate", "believe", "estimate", "expect", "intend" and similar expressions, as they relate to Innovent, are intended to identify certain of such forward-looking statements. Innovent does not intend to update these forward-looking statements regularly.

These forward-looking statements are based on the existing beliefs, assumptions, expectations, estimates, projections and understandings of the management of Innovent with respect to future events at the time these statements are made. These statements are not a guarantee of future developments and are subject to risks, uncertainties and other factors, some of which are beyond Innovent's control and are difficult to predict. Consequently, actual results may differ materially from information contained in the forward-looking statements as a result of future changes or developments in our business, Innovent's competitive environment and political, economic, legal and social conditions.

Innovent, the Directors and the employees of Innovent assume (a) no obligation to correct or update the forward-looking statements contained in this site; and (b) no liability in the event that any of the forward-looking statements does not materialize or turn out to be incorrect.

References:

1. GLOBOCAN 2024.
2. Huyghe N, et al. Biomarkers of Response and Resistance to Immunotherapy in Microsatellite Stable Colorectal Cancer: Toward a New Personalized Medicine. Cancers (Basel). 2022 Apr 29;14(9):2241.
3. Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial. Grothey, Axel et al. The Lancet, Volume 381, Issue 9863, 303 – 312.
4. Li J, Qin S, Xu R, et al. Effect of Fruquintinib vs Placebo on Overall Survival in Patients With Previously Treated Metastatic Colorectal Cancer: The FRESCO Randomized Clinical Trial. JAMA. 2018;319(24):2486–2496. doi:10.1001/jama.2018.7855.
5. Prager G et al. Trifluridine-Tipiracil and Bevacizumab in Refractory Metastatic Colorectal Cancer. N Engl J Med. 2023 May 4;388(18):1657-1667.

上海2026年8月5日 /美通社/ -- 雲頂新耀（HKEX 1952.HK），一家專注於創新藥研發、臨床開發、製造和商業化的生物製藥公司，今日宣佈公司將於北京時間2026年8月19日公佈2026年度中期業績及業務進展，並於當日舉行線上投資人會議。

會議時間：北京時間2026年8月19日，星期三，上午8:30（美國東部時間8月18日晚間8:30）

參會者可通過以下鏈接參與中文會議及英文同聲傳譯：

中文會議：

網絡參會：https://research.citics.com/tel/info/1_2232800

電話參會：

中國大陸 4008108228/4008108128
海外         861058084166
中國香港 85230051313/85230051355
中國台灣 0800666425
新加坡     6568185374
美國         16462543594
英國         441213680466
電話參會密碼：834993

同聲傳譯（英文）鏈接：

網絡參會：https://clsa.zoom.com/webinar/register/WN_CZKptYYzT5a-NKhgC7t7vw

有關雲頂新耀

雲頂新耀是一家專注於創新藥研發、臨床開發、製造和商業化的生物製藥公司，致力於滿足全球市場尚未滿足的醫療需求。雲頂新耀的管理團隊在中國及全球領先製藥企業擁有深厚的專長和豐富的經驗。公司在浙江嘉善擁有具備商業化規模的全球生產基地，並依據中國、美國及歐盟標準建立了完善的GMP生產質量管理體系。

公司聚焦自身免疫、眼科、急重症及CKM（心血管、腎臟及代謝）等疾病治療領域，已打造集全渠道商業化體系與藥品全生命週期商業化能力於一體的商業化平台，並以擁有全球權益的自研mRNA平台為基礎，持續推進mRNA in vivo CAR-T與mRNA腫瘤疫苗等現有管線，同時通過引進及生態孵化潛力平台，拓展研發能力，同時強化全球化佈局，加快國際化發展進程。更多信息，請訪問公司官網：www.everestmedicines.com。

前瞻性聲明：

本新聞稿所發佈的信息中可能會包含某些前瞻性表述，乃基於本公司或管理層在做出表述時對公司業務運營情況及財務狀況的現有看法、相信、和現有預期，可能會使用「將」、「預期」、「預測」、「期望」、「打算」、「計劃」、「相信」、「預估」、「確信」及其他類似詞語進行表述。這些前瞻性表述並非對未來業績的保證，會受到風險、不確定性及其他因素的影響，有些乃超出本公司的控制範圍，難以預計。因此，受我們的業務、競爭環境、政治、經濟、法律和社會情況的未來變化及發展等各種因素及假設的影響，實際結果可能會與前瞻性表述所含資料有較大差別。本公司及各附屬公司、各位董事、管理人員、顧問及代理未曾且概不承擔更新該稿件所載前瞻性表述以反映在本新聞稿發佈日後最新信息、未來項目或情形的任何義務，除非法律要求。

SHANGHAI, Aug. 5, 2026 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK, "Everest", or the "Company"), a biopharmaceutical company focused on the discovery, clinical development, manufacturing and commercialization of innovative therapeutics, today announced that it will report its interim results for the six months ended June 30, 2026, and provide a business update on Aug. 19, 2026. The Company will hold an online investor call on the same day.

Time: 8:30 AM Beijing Time, Wednesday, August 19, 2026 (8:30 PM U.S. Eastern Time, August 18, 2026)

For Chinese Session:

Webcast Link: https://research.citics.com/tel/info/1_2232800

Alternatively, participants may dial in to the conference call using the below dial-in information:

Chinese Mainland:     4008108228/4008108128
Overseas:                   861058084166
Hong Kong, China:    85230051313/85230051355
Taiwan, China:           0800666425
Singapore:                  6568185374
U.S.:                           16462543594
UK:                            441213680466
Password：                834993

The webcast also provides simultaneous interpretation in English:

Webcast Link: https://clsa.zoom.com/webinar/register/WN_CZKptYYzT5a-NKhgC7t7vw

About Everest Medicines

Everest Medicines is a biopharmaceutical company focused on discovering, developing, manufacturing and commercializing innovative pharmaceutical products that address critical unmet medical needs for patients in global markets. The management team of Everest Medicines has deep expertise and an extensive track record both in China and with leading global pharmaceutical companies. The Company's therapeutic areas of focus include CKM (cardiovascular, kidney, and metabolic), autoimmune, ophthalmology and critical care. Everest Medicines has developed a fully integrated commercialization platform that combines omnichannel commercial capabilities with end-to-end product lifecycle management. Leveraging its proprietary mRNA platform, the Company is advancing its existing pipeline, including mRNA in vivo CAR-T and mRNA cancer vaccines, while selectively expanding into additional high-value therapeutic areas with blockbuster potential, and accelerating its global expansion. For more information, please visit the Company's website: www.everestmedicines.com. 

Forward-Looking Statements:

This news release may make statements that constitute forward-looking statements, including descriptions regarding the intent, belief or current expectations of the Company or its officers with respect to the business operations and financial condition of the Company, which can be identified by terminology such as "will," "expects," "anticipates," "future," "intends," "plans," "believes," "estimates," "confident" and similar statements. Such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, or other factors, some of which are beyond the control of the Company and are unforeseeable. Therefore, the actual results may differ from those in the forward-looking statements as a result of various factors and assumptions, such as future changes and developments in our business, competitive environment, political, economic, legal and social conditions. The Company or any of its affiliates, directors, officers, advisors or representatives has no obligation and does not undertake to revise forward-looking statements to reflect new information, future events or circumstances after the date of this news release, except as required by law.

Apple Inc. (AAPL.US) attempted to introduce CXMT (688825.SH) as its third DRAM supplier to lower future iPhone costs, foreign reports said.

However, CXMT refused to make price concessions, with its quotations similar to or even higher than those offered by Apple's existing suppliers Samsung Electronics and SK Hynix.

Huawei, XIAOMI-W (01810.HK) and other Chinese OEM have already signed long-term supply agreements with CXMT at high prices, leaving CXMT with little incentive to compete for Apple's orders with discounted pricing, sources said.
~

AASTOCKS Financial News
Website: www.aastocks.com

Space Exploration Technologies Corp. (SPCX.US) shares plunged during pre-market trading on Wednesday (5th) after a spike in the company's AI spending raised investor concerns, overshadowing better-than-expected quarterly results. The stock last tumbled 10.4% in pre-market trading.

On Tuesday (4th), SpaceX released its first earnings report as a listed company. The space enterprise owned by CEO Elon Musk said capital expenditure in 2Q26 mushroomed sixfold to USD18.4 billion, exceeding analyst expectations, with most of the spending directed toward AI.

The company's shares closed slightly above USD125 on Tuesday, still below its IPO price of USD135 and markedly lower than the record high of more than USD200 reached shortly after listing.

During the current earnings season, market concerns have intensified over whether major technology companies can demonstrate returns from multi-billion-USD investments, weighing on investor sentiment.

Although the market believes SpaceX's proprietary models lag behind OpenAI and Anthropic, the company is positioning itself as an alternative cloud service provider by leasing computing capacity built with NVIDIA Corporation (NVDA.US) chips.

In addition, the company will face another potentially market-moving event on Thursday (6th), when the insider share lock-up period expires, allowing insiders to sell part of their holdings.
~

AASTOCKS Financial News
Website: www.aastocks.com